Sequent Scientific Limited has announced the completion of its composite scheme of amalgamation involving multiple entities, including Symed Labs Limited and Viyash Life Sciences Private Limited. The scheme became effective on December 16, 2025, which is designated as Effective Date 2. As part of the amalgamation, Sequent Scientific has approved the allotment of 18,19,21,827 equity shares of face value Rs. 2 each to the shareholders of Viyash. The share exchange ratio is 56 Sequent shares for every 100 Viyash shares. This allotment will increase the company's issued and paid-up equity share capital from Rs. 50.82 crore to Rs. 87.20 crore. Additionally, the company has approved the allotment of 2,03,41,257 share warrants to Viyash warrant holders at an issue price of Rs. 181.94 per warrant, with 25% upfront payment received. These warrants are convertible into equity shares. The company also announced significant management changes, effective December 16, 2025. Dr. Haribabu Bodepudi has been appointed as the Managing Director and Group Chief Executive Officer for a period of two years, subject to shareholder approval. Mr. Rajaram Narayanan's designation has changed to Wholetime Director, CEO – Animal Health. Mr. Srinivas Vasireddy has been appointed as an Additional Director (Wholetime and Non-Independent) for two years, also subject to shareholder approval. Furthermore, Mr. Ramakant Singani will join as Chief Financial Officer and Key Managerial Personnel from January 1, 2026. Mr. Saurav Bhala has resigned from his position as CFO and KMP, also effective January 1, 2026. The company has also noted the change in its promoter to CA Hull Investments and has altered its Memorandum and Articles of Association to reflect a revised authorized share capital of Rs. 886.14 crore, divided into 4,43,07,35,000 equity shares of Rs. 2 each.